

Rat NGAL/Lipocalin-2 Immunoassay

Catalog Number: EA800183

For the quantitative determination of rat NGAL/Lipocalin-2 concentrations in cell culture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

MANUFACTURED AND DISTRIBUTED BY:

OriGene Technologies, Inc.

9620 Medical Center Drive Suite 200 Rockville, MD 20850,USA



TABLE OF CONTENTS

SECTION	PAGE
BACKGROUND	1
PRINCIPLE OF THE ASSAY	1
TECHNICAL HINTS AND LIMITATIONS	2
PRECAUTIONS	2
KIT COMPONENTS& STORAGE CONDITIO	NS3
OTHER SUPPLIES REQUIRED BUT NOT SU	PPLIED4
SPECIMEN COLLECTION & STORAGE	4
REAGENTS PREPARATION	4
ASSAY PROCEDURE	6
CALCULATION OF RESULTS	6
PERFORMANCE CHARACTERISTICS	
REFERENCES	




BACKGROUND

Lipocalin-2(LCN2), also known as NGAL, is a protein associated with neutrophil gelatinase. The LCN2 gene is located at 9q34 and contains 7 exons. The 25-kD LCN2 protein is believed to bind small lipophilic substances such as bacteria-derived lipopolysaccharide(LPS) and formylpeptides and may function as a modulator of inflammation. NGAL tightly binds bacterial catecholate-type ferric siderophores through a cyclically permuted, hybrid electrostatic/cation-pi interaction and is a potent bacteriostatic agent in iron-limiting conditions. The primary LCN2 transcript is 3,696 nucleotides long, and the processed transcript is 809 nucleotides long. LCN2 expression in adult bone marrow, uterus, prostate, salivary gland, stomach, appendix, colon, trachea, and lung, and in fetal spleen and lung. The standard product used in this kit is recombinant rat NGAL, consisting of 177 amino acids with the molecular mass of 21kDa.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for NGAL/Lipocalin-2 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any NGAL/Lipocalin-2 present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for NGAL/Lipocalin-2 is added to detect the captured NGAL/Lipocalin-2 protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.



Schematic diagram:



- 1. This OriGene ELISA should not be used beyond the expiration data on the kit label.
- 2. To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3. To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4. A thorough and consistent wash technique is essential for proper assay performance.
- 5. A standard curve should be generated for each set of samples assayed.
- 6. It is recommended that all standards and samples be assayed in duplicate.
- 7. Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

PRECAUTIONS

The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

KIT COMPONENTS& STORAGE CONDITIONS



PART	SIZE	STORAGEOFOPENED/RECONSTITUTED MATERIAL
Microwell Plate - antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at $2 - 8^{\circ}C^{**}$
Standard - lyophilized,5000 pg/ml upon reconstitution	2 vials	Aliquot and Store at -20°C** for six months
Concentrated Biotin-Conjugated antibody (100X) - 120 ul/vial	1 vial	Store at 2-8°C **for six months
Concentrated Streptavidin-HRP solution (100X) - 120 ul/vial	1 vial	Store at 2-8°C** for six months
Standard/Sample Diluent - 16 ml/ vial	1 bottle	Store at 2-8°C** for six months
Biotin-ConjugateantibodyDiluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Streptavidin-HRP Diluent - 16 ml/vial	1 bottle	Store at 2-8°C** for six months
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8°C** for six months
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8°C** for six months
Plate Cover Seals	4 pieces	

******Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

1. Microplate reader capable of measuring absorbance at 450 nm.



- 2. Pipettes and pipette tips.
- 3. Deionized or distilled water.
- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5. 500 mL graduated cylinder.

SPECIMEN COLLECTION & STORAGE

Cell Culture Supernates - Centrifuge cell culture media at $1000 \times \text{g}$ to remove debris. Assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at

room temperature or overnight at 2-8°C. Centrifuge approximately for 15 minutes at

1000×g. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.


Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000×g within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Note: The normal rat serum or plasma samples are suggested to make a 1:2 dilution.

REAGENTS PREPARATION

- **1. Temperature returning** Bring all kit components and specimen to room temperature (20-25°C) before use.
- 2. Wash Buffer Dilute 30mL of Wash Buffer Concentrate with 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mix gently until the crystals have completely dissolved.
- 3. Standard/Sample Reconstitute the Standard with 0.5mL of Standard/Sample Diluent. This reconstitution produces a stock solution of 5000pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 250µL of Standard/Sample Diluent into 2500pg/ml tube and the remaining tubes. Use the stock solution of 5000pg/mL to produce a 2-fold dilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 5000 pg/mL standard serves as the high standard. The Standard/ Sample Diluent serves as the zero standard (0 pg/mL).





Preparation of NGAL/Lipocalin-2 standard dilutions

*If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.

4. Working solution of Biotin-Conjugate anti-rat NGAL/Lipocalin-2 antibody: Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.

5. Working solution of Streptavidin-HRP: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.

ASSAY PROCEDURE

Prepare all reagents and standards as directed. Wash the plate 3 times before assay.



Add 100µl standard or samples to each well, incubate 90 minutes,37°C.			
Aspirate and wash 4 times			
Add 100µl working solution of Biotin-Conjugate anti-rat NGAL/Lipocalin-2 antibody to each well, incubate 60 minutes,37°C.			
Aspirate and wash 4 times			
Add 100µl working solution of Streptavidin-HRP to each well, incubate 30 minutes,37°C.			
\square Aspirate and wash 5 times			
Add 100µl Substrate solution to each well, incubate 15 minutes,37°C.Protect from light.			
Ţ.			
Add 50µl Stop solution to each well. Read at 450nm within 5 minutes.			

Π

CALCULATION OF RESULTS


- 1. The standard curve is used to determine the amount of specimens.
- 2. First, average the duplicate readings for each standard, control, and sample. All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the NGAL/Lipocalin-2 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- 5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Standard(pg/ ml)	OD.	OD.	Average	Corrected
0	0.018	0.022	0.020	-

Typical data using the NGAL/Lipocalin-2 ELISA



78.1	0.256	0.250	0.253	0.233
156.2	0.296	0.289	0.292	0.272
312.5	0.440	0.430	0.435	0.415
625	0.698	0.683	0.691	0.671
1250	1.134	1.109	1.121	1.102
2500	1.847	1.805	1.826	1.806
5000	3.009	2.941	2.975	2.955



Representative standard curve for NGAL/Lipocalin-2 ELISA

Performance Characteristics

SENSITIVITY: The minimum detectable dose was 35pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant rat



NGAL/Lipocalin-2. The factors listed below were prepared at 100ng/ml in Standard / Sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.

Factors assayed for cross-reactivity

Recombinant rat	Recombinant mouse	Recombinant human
MMP-9		Lipocalin-1
		Lipocalin-2

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of NGAL/Lipocalin-2 spiked to three different levels in

four samples throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % of Expected Range (%)	Range (%)
Citrate plasma	90	88-92
Cell culture supernatants	108	97-119

Recovery of NGAL/Lipocalin-2 in two matrices

LINEARITY: To assess the linearity of the assay, three samples were spiked with high concentrations of NGAL/Lipocalin-2 in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. (The plasma samples were initially diluted 1:1)



Dilution ratio	Recovery (%)	Citrate plasma	Cell culture supernatants
1:2	Average% of Expected	104	102
	Range (%)	99-109	99-105
1:4	Average% of Expected	108	105
	Range (%)	104-112	100-110
1.0	Average% of Expected	96	105
1:8	Range (%)	89-104	95-114
1:16	Average% of Expected	101	103
	Range (%)	93-113	92-111

REFERENCES

- 1. Flower, D.R. (1996) Biochem. J. 318:1.
- 2. Schlehuber, S. and A. Skerra (2005) Drug Discov. Today 10:23.
- 3. Flower, D.R. (1994) FEBS Lett. 354:7.



- 4. Kjeldsen, L. et al. (2000) Biochim. Biophys. Acta 1482:272.
- 5. Kjeldsen, L. et al. (1993) J. Biol. Chem. 268:10425.
- 6. Friedl, A. et al. (1999) Histochem. J. 31:433.
- 7. Devireddy, L.R. et al. (2001) Science 293:829.
- 8. Yang, J. et al. (2002) Mol. Cell 10:1045.
- 9. Flo, T.H. et al. (2004) Nature 432:917.
- 10. Yan, L. et al. (2001) J. Biol. Chem. 276:37258.
- 11. Goetz, D.H. et al. (2002) Mol. Cell 10:1033.
- 12. Berger, T. et al. (2006) Proc. Natl. Acad. Sci. USA 103:1834.
- 13. Yang, J. et al. (2003) Am. J. Physiol. Renal Physiol. 285:F9.
- 14. Mori, K. et al. (2005) J. Clin. Invest. 115:610.
- 15. Mishra, J. et al. (2005) Lancet 365:1231.
- 16. Hvidberg, V. et al. (2005) FEBS Lett. 579:773.
- 17. Devireddy, L.R. et al. (2005) Cell 123:1293.
- 18. Tong, Z. et al. (2005) Biochem. J. 391:441.
- 19. Klausen, P. et al. (2005) Eur. J. Haematol. 75:332.
- 20. Seo, S.J. et al. (2006) J. Invest. Dermatol. 126:510.